These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 19423276)
61. Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity? van den Berg MP; van Spaendonck-Zwarts KY; van Veldhuisen DJ; Gietema JA; Postma A; van Tintelen JP Eur J Heart Fail; 2010 Dec; 12(12):1297-9. PubMed ID: 20952769 [No Abstract] [Full Text] [Related]
62. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Conklin KA Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925 [TBL] [Abstract][Full Text] [Related]
63. Assessment of left ventricular systolic dysfunction by tissue Doppler imaging to detect subclinical cardiomyopathy early after anthracycline therapy. Lotrionte M; Palazzoni G; Natali R; Comerci G; Abbate A; Loperfido F; Biondi-Zoccai G Minerva Cardioangiol; 2007 Dec; 55(6):711-20. PubMed ID: 18091640 [TBL] [Abstract][Full Text] [Related]
64. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia. Rathe M; Carlsen NL; Oxhøj H; Nielsen G Pediatr Blood Cancer; 2010 Mar; 54(3):444-8. PubMed ID: 19830828 [TBL] [Abstract][Full Text] [Related]
65. Rational and design of SATRACD study: detecting subclinical anthracycline therapy related cardiac dysfunction in low income country. Zhang W; Azibani F; Okello E; Kayima J; Walusansa V; Orem J; Sliwa K Afr Health Sci; 2021 Jun; 21(2):647-654. PubMed ID: 34795719 [TBL] [Abstract][Full Text] [Related]
66. [Cardiotoxicity of anthracyclines]. Costache II; Petriş A Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470 [TBL] [Abstract][Full Text] [Related]
67. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. Hequet O; Le QH; Moullet I; Pauli E; Salles G; Espinouse D; Dumontet C; Thieblemont C; Arnaud P; Antal D; Bouafia F; Coiffier B J Clin Oncol; 2004 May; 22(10):1864-71. PubMed ID: 15143078 [TBL] [Abstract][Full Text] [Related]
68. Suspected post-chemotherapy cardiomyopathy hiding severe three-vessel coronary artery disease in a young patient with metabolic syndrome: should an early angiography be recommended? Cecchi E; Calabretta R; Mattesini A; Gensini GF; Giglioli C Acta Med Iran; 2012; 50(10):707-9. PubMed ID: 23275288 [TBL] [Abstract][Full Text] [Related]
69. Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study. Lotrionte M; Palazzoni G; Natali R; Comerci G; Abbate A; Di Persio S; Biondi-Zoccai GG Int J Cardiol; 2009 Jun; 135(1):72-7. PubMed ID: 18572266 [TBL] [Abstract][Full Text] [Related]
70. Can comprehensive echocardiographic evaluation provide an advantage to predict anthracycline-induced cardiomyopathy? Erdoğan D; Yücel H; Alanoğlu EG; Uysal BA; Koçer M; Ozaydın M; Doğan A Turk Kardiyol Dern Ars; 2011 Dec; 39(8):646-53. PubMed ID: 22257802 [TBL] [Abstract][Full Text] [Related]
71. Approach to Lymphoma-Associated Cardiomyopathy. Abouzid MRA; Hameed M; Katta MR; Valisekka SS Cardiol Rev; 2024 Mar-Apr 01; 32(2):104-109. PubMed ID: 36129332 [TBL] [Abstract][Full Text] [Related]
72. The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy. Cavarretta E; Mastroiacovo G; Lupieri A; Frati G; Peruzzi M Adv Exp Med Biol; 2017; 1000():103-129. PubMed ID: 29098619 [TBL] [Abstract][Full Text] [Related]
73. [The role of dobutamine stress echocardiography in early diagnosis of cardiac toxicity in long-term survivors of asymptomatic children treated with anthracycline]. Yildirim A; Tunaoğlu FS; Pinarli FG; Ilhan M; Oğuz A; Karadeniz C; Olguntürk R; Oğuz D; Kula S Anadolu Kardiyol Derg; 2010 Apr; 10(2):154-62. PubMed ID: 20382616 [TBL] [Abstract][Full Text] [Related]
75. [Long-term selective beta 1-blockade therapy for a patient with anthracycline-induced cardiomyopathy]. Okamoto M; Miyazaki H; Tsuzuki M; Ino T; Ezaki K; Hirano M Rinsho Ketsueki; 1995 Nov; 36(11):1305-10. PubMed ID: 8691573 [TBL] [Abstract][Full Text] [Related]
76. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Geisberg CA; Sawyer DB Curr Hypertens Rep; 2010 Dec; 12(6):404-10. PubMed ID: 20842465 [TBL] [Abstract][Full Text] [Related]
77. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Jensen BV Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285 [TBL] [Abstract][Full Text] [Related]
78. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients. Anderson B Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251 [TBL] [Abstract][Full Text] [Related]
79. Cardiac functions evaluated with tissue Doppler imaging in childhood cancers treated with anthracyclines. Baysal T; Koksal Y; Oran B; Sen M; Unal E; Cimen D Pediatr Hematol Oncol; 2010 Feb; 27(1):13-23. PubMed ID: 20121551 [TBL] [Abstract][Full Text] [Related]
80. [Early detection of anthracyclines cardiotoxicity by tissue Doppler echocardiography about 45 cases at Abidjan institute of cardiology]. Pio M; Adoubi K; Adoh A; Didi-Kouko C; Anzouan-Kacou JB; Tegnan A; Adoubi I Ann Cardiol Angeiol (Paris); 2013 Feb; 62(1):28-33. PubMed ID: 22513244 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]